Van ECK Associates Corp Acquires 65,622 Shares of DexCom, Inc. (NASDAQ:DXCM)

Van ECK Associates Corp lifted its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 325.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 85,813 shares of the medical device company's stock after purchasing an additional 65,622 shares during the quarter. Van ECK Associates Corp's holdings in DexCom were worth $6,674,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Crossmark Global Holdings Inc. boosted its stake in DexCom by 1.0% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 18,778 shares of the medical device company's stock valued at $1,259,000 after purchasing an additional 182 shares during the last quarter. GPS Wealth Strategies Group LLC boosted its position in shares of DexCom by 13.2% during the fourth quarter. GPS Wealth Strategies Group LLC now owns 1,587 shares of the medical device company's stock valued at $123,000 after buying an additional 185 shares during the last quarter. Peterson Wealth Services grew its holdings in DexCom by 7.1% during the fourth quarter. Peterson Wealth Services now owns 3,030 shares of the medical device company's stock worth $236,000 after buying an additional 201 shares in the last quarter. Magnolia Capital Advisors LLC raised its position in DexCom by 2.6% in the 4th quarter. Magnolia Capital Advisors LLC now owns 8,198 shares of the medical device company's stock valued at $638,000 after buying an additional 210 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB raised its position in DexCom by 46.7% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company's stock valued at $65,000 after buying an additional 265 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Trading Down 0.6 %

DXCM traded down $0.56 during trading on Friday, hitting $88.78. 3,729,437 shares of the stock traded hands, compared to its average volume of 3,632,823. The firm has a market capitalization of $34.69 billion, a P/E ratio of 62.08, a price-to-earnings-growth ratio of 2.31 and a beta of 1.14. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The firm has a 50-day moving average of $83.26 and a 200 day moving average of $75.94.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Equities research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Buying and Selling at DexCom

In related news, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the transaction, the chief executive officer now directly owns 319,037 shares of the company's stock, valued at $27,727,505.67. This represents a 9.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Jacob Steven Leach sold 2,634 shares of the firm's stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the sale, the chief operating officer now owns 268,644 shares of the company's stock, valued at $23,347,850.04. This trade represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 38,083 shares of company stock valued at $3,309,794 in the last 90 days. Insiders own 0.30% of the company's stock.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Raymond James reduced their target price on shares of DexCom from $115.00 to $99.00 and set a "strong-buy" rating for the company in a research note on Friday, October 25th. Wells Fargo & Company upped their price objective on shares of DexCom from $90.00 to $94.00 and gave the stock an "overweight" rating in a research report on Wednesday, December 11th. StockNews.com cut shares of DexCom from a "buy" rating to a "hold" rating in a research report on Saturday, November 2nd. Oppenheimer cut their target price on DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research note on Friday, October 25th. Finally, Royal Bank of Canada decreased their price target on DexCom from $120.00 to $115.00 and set an "outperform" rating for the company in a research report on Friday, October 25th. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $99.06.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.